Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025

Adaptive Biotechnologies Corp

Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.
Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.
Company released from exclusivity obligations in oncology cell therapies.
Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.